The COVID-19 pandemic has affected the entire world in an unprecedented way, and this book provides an overview of the historical facts as well as ongoing approaches to tackle the COVID-19 pandemic. Experts of the respective domains provide details on anti-SARS-CoV-2 drug strategies, including repurposing drugs used for other indications and the development of novel drugs looking at different approaches to target virus entry and replication. COVID-19 vaccine development based on inactivated and attenuated live virus, protein subunit and peptide-based vaccines and utilization of vaccine candidates based on viral vectors, DNA and RNA are presented for both preclinical studies and clinical trials.
Key Features
Explains the background of the COVID-19 pandemic, the current progress in the development of treatments and prevention of COVID-19 including future aspects of dealing with the pandemic
Serves as a timely repository of knowledge on COVID-19 for researchers and medical professionals engaged in its management
Edited by:
Debmalya Barh (UFMG Brazil.),
Kenneth Lundstrom (PanTherapeutics,
Switzerland)
Imprint: CRC Press
Country of Publication: United Kingdom
Dimensions:
Height: 254mm,
Width: 178mm,
Weight: 607g
ISBN: 9781032040639
ISBN 10: 1032040637
Pages: 222
Publication Date: 04 March 2022
Audience:
Professional and scholarly
,
College/higher education
,
Undergraduate
,
Further / Higher Education
Format: Hardback
Publisher's Status: Active
Chapter 1 Coronavirus epidemics and the current COVID-19 pandemic Chapter 2 Biology of Coronaviruses and Predicted Origin of SARS-CoV-2 Chapter 3 Therapeutic Challenges in COVID-19 Chapter 4 Prevention and Control Strategies for COVID-19 Pandemic Chapter 5 Global Focus and Interdisciplinary Approaches in COVID-19 Research and Their Outcomes Chapter 6 The evolution of COVID-19 diagnostics Chapter 7 Drug repurposing and novel antiviral drugs for COVID-19 management Chapter 8 Convalescent Plasma and Antibody Therapy in COVID-19 Chapter 9 Application Stem Cell and Exosome Based Therapy in COVID-19 Chapter 10 Host and Pathogen-Specific Drug Targets in COVID-19 Chapter 11 Computational biology and bioinformatics in anti-SARS-CoV-2 drug development Chapter 12 Nanomaterials in COVID-19 drug development Chapter 13 Vaccine Development Strategies and the Current Status of COVID-19 Vaccines Chapter 14 Clinical trials of COVID-19 therapeutics and vaccines: history, current status, and limitations Chapter 15 Lessons Learned from COVID-19 and Their Implementations for Future Pandemics
Dr. Debmalya Barh is currently a Visiting Full Professor (Titular, Grade-E) at the Department of Genetics, Ecology and Evolution, Institute of Biological Sciences (ICB), Federal University of Minas Gerais (UFMG), Brazil. He is also an honorary Scientist at Institute of Integrative Omics and Applied Biotechnology (IIOAB), India. Dr. Kenneth Lundstrom is currently the CEO of PanTherapeutics in Lausanne, Switzerland.He serves on editorial boards of various journals including Biomedicines and Viruses, and acts as Editor-in-chief for Frontiers in Translational Virology.
